Asset profile
RAP-219
Small molecule
Evidence outlook · registrational
Epilepsy: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2029-07.
NCT06377930: The study enrolled 30 participants in a single, open-label RAP-219 group without randomization or a placebo/active comparator, relying on within-participant baseline comparisons for the clinical seizure endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Focal Onset Seizures · Phase 2Peripheral Neuropathic Pain
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 43 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| RAP-219: this drug | Phase 3 | Small molecule | AMPA receptor (TARP γ8-dependent) | ||
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | ||
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | ||
| Carbamazepine | Approved | Small molecule | Sodium channels | ||
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | ||
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | ||
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | ||
| Diastat | Approved | Combination | GABA-A receptor | ||
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | ||
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor | ||
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | ||
| Eslicarbazepine Acetate (Aptiom) | Approved | Small molecule | Voltage-gated sodium channel | ||
| Ethosuximide | Approved | Small molecule | T-type calcium channel | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Ezogabine (Potiga) | Approved | Small molecule | Kv7 potassium channel | ||
| Felbamate | Approved | Small molecule | NMDA receptor (glycine site, antagonist) |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
February 2028 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.